Laman UtamaCRSP • NASDAQ
add
Crispr Therapeutics AG
$37.78
Selepas Waktu Dagangan:(0.00%)0.00
$37.78
Tutup: 16 Apr, 4:35:27 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$38.95
Julat hari
$36.74 - $38.50
Julat tahun
$30.06 - $67.88
Permodalan pasaran
3.24B USD
Bilangan Purata
2.16J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 35.69J | -82.26% |
Perbelanjaan pengendalian | 18.12J | 9.98% |
Pendapatan bersih | -37.31J | -141.76% |
Margin untung bersih | -104.54 | -335.40% |
Pendapatan bagi setiap syer | -0.44 | -140.00% |
EBITDA | -59.75J | -180.21% |
Kadar cukai berkesan | -1.91% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.90B | 12.41% |
Jumlah aset | 2.24B | 0.56% |
Jumlah liabiliti | 309.95J | -10.62% |
Jumlah ekuiti | 1.93B | — |
Syer tertunggak | 85.77J | — |
Harga kepada buku | 1.73 | — |
Pulangan pada aset | -7.18% | — |
Pulangan pada modal | -7.47% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -37.31J | -141.76% |
Tunai daripada operasi | -50.03J | 47.92% |
Tunai daripada pelaburan | 105.83J | 229.93% |
Tunai daripada pembiayaan | 16.88J | -56.66% |
Perubahan bersih dalam tunai | 72.59J | 152.40% |
Aliran tunai bebas | -41.33J | 68.36% |
Perihal
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Diasaskan
2013
Ibu pejabat
Tapak web
Pekerja
393
